Hashimoto, Kenji

Nervous system involvement after infection with COVID-19 and other coronaviruses

Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., Liu, C., & Yang, C. (2020) · Brain, Behavior, and Immunity

Long-Term Effects of COVID-19Infectious Encephalopathies and Encephalitis

Cited by 2,046

Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants

Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 1,151

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 605

Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets

Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology

Tryptophan and brain disordersTreatment of Major Depression

Cited by 538

Critical Role of Brain-Derived Neurotrophic Factor in Mood Disorders

Hashimoto, K., Shimizu, E., & Iyo, M. (2004) · Brain Research Reviews

Treatment of Major DepressionNerve injury and regeneration

Cited by 522

Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia

Ozawa, K., Hashimoto, K., Kishimoto, T., Shimizu, E., Ishikura, H., & Iyo, M. (2006) · Biological Psychiatry

Tryptophan and brain disordersSchizophrenia research and treatment

Cited by 467

Brain‐derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions

Hashimoto, K. (2010) · Psychiatry and Clinical Neurosciences

Treatment of Major DepressionNerve injury and regeneration

Cited by 388

Emerging role of glutamate in the pathophysiology of major depressive disorder

Hashimoto, K. (2009) · Brain Research Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 381

R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior

Treatment of Major DepressionTryptophan and brain disorders

Cited by 357

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 335

Antidepressant Effects of TrkB Ligands on Depression-Like Behavior and Dendritic Changes in Mice After Inflammation

Zhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 289

Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry

Schizophrenia research and treatmentAmino Acid Enzymes and Metabolism

Cited by 267

Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain

Narita, N., Hashimoto, K., Tomitaka, S.-I., & Minabe, Y. (1996) · European Journal of Pharmacology

Pharmacological Receptor Mechanisms and EffectsNeurotransmitter Receptor Influence on Behavior

Cited by 254

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine

Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionTryptophan and brain disorders

Cited by 252

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 248

Microglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine

Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 216

The gut-liver axis in sepsis: interaction mechanisms and therapeutic potential

Zhang, X., Liu, H., Hashimoto, K., Yuan, S., & Zhang, J. (2022) · Critical Care

Sepsis Diagnosis and TreatmentGut microbiota and health

Cited by 200

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 190

Alteration of Plasma Glutamate and Glutamine Levels in Children with High-Functioning Autism

Shimmura, C., Suda, S., Tsuchiya, K. J., Hashimoto, K., Ohno, K., Matsuzaki, H., Iwata, K., Matsumoto, K., Wakuda, T., Kameno, Y., et al. (2011) · PLoS ONE

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 189

Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression

Zhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 183

Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut–microbiota–brain axis

Zhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., & Hashimoto, K. (2017) · Translational Psychiatry

Tryptophan and brain disordersTreatment of Major Depression

Cited by 182

Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine

Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 176

Key role of gut microbiota in anhedonia-like phenotype in rodents with neuropathic pain

Yang, C., Fang, X., Zhan, G., Huang, N., Li, S., Bi, J., Jiang, R., Yang, L., Miao, L., Zhu, B., et al. (2019) · Translational Psychiatry

Gut microbiota and healthPain Mechanisms and Treatments

Cited by 176

Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice

Yao, W., Zhang, J.-C., Ishima, T., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Suganuma, H., et al. (2016) · Scientific Reports

Tryptophan and brain disordersGenomics, phytochemicals, and oxidative stress

Cited by 154